Meniere hastalığında intratimpanik tedavi: Gentamisin ve deksametazonun vertigo kontrolü ve işitme üzerine etkisi

Amaç: Meniere hastalığı› tedavisinde güncel uygulamalar olan intratimpanik gentamisin ve deksametazon tedavisinin vertigo kontrolü işitme üzerine olan etkileri araştırıldı Hastalar ve Yöntemler: Amerikan Otorinolarengoloji Başlı Boyun Cerrahisi Akademisi’nin 1995 ölçütlerine göre Meniere hastalığı tanısı konan 24 hastaya 11 erkek, 13 kadın; ort. yaşlı 46 intratimpanik gentamisin 40 mg/ml, 0.7 ml , 21 hastaya 8 erkek, 13 kadın; ort. yafl 50.4 ise intratimpanik deksametazon 4 mg/ml, 0.7 ml uygulandı. Tedavinin vertigo ve işlitme semptomları üzerine etkisi değerlendirildi. Bulgular: Gentamisin grubunda 22 hastada %92 vertigo kontrolü sağlandı, yaln›zca iki hastada %8 iflitmede kötüleflme görüldü. Deksametazon grubunda, 21 hastan›n dokuzunun takipleri tamamland›. Bunlar›n altısında %67 vertigo kontrolü sağlanırken, işlitmesi kötüleşlen hasta olmadı, bir hastanın %5 işlitmesinde düzelme görüldü. işitmede düzelme en az 5 dB’lik değiflme olarak tan›mlandığında, bu grupta işlitmede düzelme görülen hasta sayısı befl %24 idi. Sonuç: Meniere hastalığı tedavisinde intratimpanik tedaviler, uygulaması kolay, ucuz ve etkili, aynı zamanda gelecekte daha genişl uygulama alanları ve daha yüksek başları oranları beklenen yöntemlerdir.

Intratympanic treatment in Meniere's disease: the effect of gentamicin and dexamethasone on vertigo control and hearing

Objectives: We investigated the effect of intratym- panic gentamicin and dexamethasone treatments on the control of vertigo and hearing loss in patients with Meniere's disease.Patients and Methods: Forty-five patients with a diag- nosis of Meniere's disease according to the 1995 crite- ria of American Academy of Otorhinolaryngology Head and Neck Surgery were assigned to receive intratym- panic gentamicin 40 mg/ml, 0.7 mİ; n=24; 11 males, 13 females; mean age 46 years or dexamethasone 4 mg/ml, 0.7 mİ; n=21; 8 males, 13 females; mean age 50.4 years . The results were evaluated with respect to changes in vertigo and hearing symptoms.Results: İn the gentamicin group, vertigo symptoms were controlled in 22 patients 92% , deterioration in hearing was seen in only two patients 8% . İn the dex- amethasone group, nine patients had complete follovv- up. Of these, vertigo control was achieved in six patients 67% , none had vvorsened hearing, and one patient 5% had improved hearing. When improve- ment in hearing was defined as at least a 5 dB change, then five patients 24% benefited from treatment.Conclusion: Intratympanic treatment modalities in Meniere's disease are easy to perform, cheap, and effective. They are expected to have a more exten- sive use with higher success rates in the future.

___

  • Paparella MM, Fina M. Endolymphatic sac enhance- ment: reversal of pathogenesis. Otolaryngol Clin North [Am] 2002;35:621-37.
  • Pappas DG Jr, Pappas DG Sr. Vestibular nerve section: long-term follow-up. Laryngoscope 1997;107:1203-9.
  • Thomsen J, Berner B, Tos M. Vestibular neurectomy. Auris Nasus Larynx 2000;27:297-301.
  • Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Meniere's disease. American Academy of Otolaryngology-Head and Neck Foundation, Inc. Otolaryngol Head Neck Surg 1995;113:181-5.
  • Thai-Van H, Bounaix MJ, Fraysse B. Meniere's disease: pathophysiology and treatment. Drugs 2001;61:1089- 102.
  • Baloh RW. Harold Schuknecht and pathology of the ear. Otol Neurotol 2001;22:113-22.
  • Sennaroglu L, Linthicum FH Jr. Histopathology of Meniere’s disease. Am J Otol 2000;21:889.
  • Fraysse BG, Alonso A, House WF. Meniere’s disease and endolymphatic hydrops: clinical-histopathologi- cal correlations. Ann Otol Rhinol Laryngol Suppl 1980;89(6 Pt 3):2-22.
  • Schuknecht HF. Ablation therapy for the relief of Meniere’s disease. Laryngoscope 1956;66:859-70.
  • Nedzelski JM, Schessel DA, Bryce GE, Pfleiderer AG. Chemical labyrinthectomy: local application of gen- tamicin for the treatment of unilateral Meniere's dis- ease Am J Otol 1992;13:18-22.
  • Berryhill WE, Graham MD. Chemical and physical labyrinthectomy for Meniere’s disease. Otolaryngol Clin North [Am] 2002;35:675-82.
  • Thomsen J, Charabi S, Tos M. Preliminary results of a new delivery system for gentamicin to the inner ear in patients with Meniere’s disease. Eur Arch Otorhinolaryngol 2000;257:362-5.
  • DeCicco MJ, Hoffer ME, Kopke RD, Wester D, Allen KA, Gottshall K, et al. Round-window microcatheter- administered microdose gentamicin: results from treatment of Tinnitus Associated with Meniere’s Disease. Int Tinnitus J 1998;4:141-3.
  • Silverstein H, Jackson LE, Rosenberg SI. Silverstein MicroWick for the treatment of inner ear disease. Operative Techniques in Otolaryngology-Head and Neck Surgery 2001;12:144-7.
  • Hoffer ME, Kopke RD, Weisskopf P, Gottshall K, Allen K, Wester D. Microdose gentamicin administration via the round window microcatheter: results in patients with Meniere’s disease. Ann N Y Acad Sci 2001;942:46-51.
  • Quaranta A, Aloisi A, De Benedittis G, Scaringi A: Intratympanic therapy for Meniere's disease. High- concentration gentamicin with round-window protec- tion. Ann N Y Acad Sci 1999;884:410-24.
  • Kaasinen S, Pyykko I, Ishizaki H, Aalto H. Intratympanic gentamicin in Meniere’s disease. Acta Otolaryngol 1998;118:294-8.
  • Blakley BW. Update on intratympanic gentamicin for Meniere's disease. Laryngoscope 2000;110:236-40.
  • Wu IC, Minor LB. Long-term hearing outcome in patients receiving intratympanic gentamicin for Meniere’s disease. Laryngoscope 2003;113:815-20.
  • Marzo SJ, Leonetti JP. Intratympanic gentamicin thera- py for persistent vertigo after endolymphatic sac surgery. Otolaryngol Head Neck Surg 2002;126:31-3.
  • Ünlü M, Yiğit Ö, Çınar U, Akgül G, Alkan S, Turgut S ve ark. Meniere hastalığında ventilasyon tüpü yolu ile intratimpanik gentamisin uygulaması. Kulak Burun Boğaz ve Baş Boyun Cerrahisi 2002;10:63-6.
  • Erişir F, Aydın S, Güçlü E, Güvenç G, İnci E, Sancak Y. Meniere hastalığında intratimpanik gentamisin teda- visinin yeri. Haseki Tıp Bülteni 2001;39:87-91.
  • Jackson LE, Silverstein H. Chemical perfusion of the inner ear. Otolaryngol Clin North [Am] 2002;35:639-53.
  • Barrs DM, Keyser JS, Stallworth C, McElveen JT Jr. Intratympanic steroid injections for intractable Meniere’s disease. Laryngoscope 2001;111:2100-4.
  • Parnes LS, Sun AH, Freeman DJ. Corticosteroid phar- macokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope 1999; 109(7 Pt 2):1-17.
  • Hamid M, Sismanis A. Meniere’s disease and immune mediated inner ear disease. Curr Opin Otolaryngol Head Neck Surg 2001;9:319-22.
  • Arriaga MA, Goldman S. Hearing results of intratym- panic steroid treatment of endolymphatic hydrops. Laryngoscope 1998;108:1682-5.
  • Shea JJ Jr, Ge X. Dexamethasone perfusion of the labyrinth plus intravenous dexamethasone for Meniere’s disease. Otolaryngol Clin North [Am] 1996; 29:353-8.
  • Itoh A, Sakata E. Treatment of vestibular disorders. Acta Otolaryngol Suppl 1991;481:617-23.
  • Erişir F, Şenocak D, Güçlü E, Hızlı C, İnci E. Meniere hastalarında transtimpanik deksametazon tedavisi ve sonuçlarımız. KBB Postası 2001; 11:1-4.
  • Yılmaz İ, Akkuzu B, Özlüoğlu LN. İntratimpanik uy- gulamalar: popüler bir yöntem üzerine derleme. Otos- kop Dergisi 2003;3:145-155.
  • Sennaroglu L, Sennaroglu G, Gursel B, Dini FM. Int- ratympanic dexamethasone, intratympanic gentami- cin, and endolymphatic sac surgery for intractable ver- tigo in Meniere’s disease. Otolaryngol Head Neck Surg 2001;125:537-43.
  • Chia SH, Gamst AC, Anderson JP, Harris JP. Intratympanic gentamicin therapy for Meniere’s disease: a meta-analysis. Otol Neurotol 2004;25:544-52.